Listed

CVS HEALTH Corp: Form 10-Q for the period ended Jun 30, 2018

Filed with the SEC on Aug 8, 2018 and accepted by EDGAR at Aug 8, 2018, 07:12 ET.

Share

Management's discussion and analysis

As filed, 1,051 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.

(c) Stock Repurchases

The following table presents the total number of shares purchased in the three months ended June 30, 2018, the average price paid per share and the approximate dollar value of shares that still could have been purchased at the end of the applicable fiscal period, pursuant to the 2016 Repurchase Program. See “Note 5 - Share Repurchase Programs” contained in the “Notes to the Condensed Consolidated Financial Statements” of our Quarterly Report on Form 10‑Q for the three months ended June 30, 2018.

Fiscal Period Total Number of Shares Purchased Average Price Paid per Share Total Number of Shares Purchased as Part of Publicly Announced Plans or Programs Approximate Dollar Value of Shares that May Yet Be Purchased Under the Plans or Programs
April 1, 2018 through April 30, 2018 — $— — $13,869,392,446
May 1, 2018 through May 31, 2018 — $— — $13,869,392,446
June 1, 2018 through June 30, 2018 — $— — $13,869,392,446
— —

51

Market risk

As filed, 335 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.

As of June 30, 2018, the Company did not have any interest rate, foreign currency exchange rate or commodity derivative instruments in place and believes that as of June 30, 2018 its exposure to interest rate risk (inherent in the Company’s debt portfolio), foreign currency exchange rate risk and commodity price risk is not material.

Controls and procedures

As filed, 1,054 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.

Evaluation of disclosure controls and procedures: The Company’s Chief Executive Officer and Chief Financial Officer, after evaluating the effectiveness of the design and operation of the Company’s disclosure controls and procedures (as defined in Securities Exchange Act Rules 13a‑15(f) and 15d‑15(f)) as of June 30, 2018, have concluded that as of such date the Company’s disclosure controls and procedures were adequate and effective and designed to provide reasonable assurance that material information relating to the Company and its subsidiaries would be made known to such officers on a timely basis.

Changes in internal control over financial reporting: There have been no changes in our internal control over financial reporting identified in connection with the evaluation required by paragraph (d) of Securities Exchange Act Rule 13a‑15 or Rule 15d‑15 that occurred in the three months ended June 30, 2018 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

50

Figures reported in this filing

Standardized line items from the XBRL in this filing, for the period ended 2018-06-30. Comparative periods it repeats are left out.

Figures reported in this filing
Line itemPeriodValueXBRL concept
Revenue3 months2018-04-01 to 2018-06-30$46.71bnus-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
Revenue6 months2018-01-01 to 2018-06-30$92.40bnus-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
Cost of revenue3 months2018-04-01 to 2018-06-30$39.51bnus-gaap:CostOfGoodsAndServicesSold
Cost of revenue6 months2018-01-01 to 2018-06-30$78.34bnus-gaap:CostOfGoodsAndServicesSold
Gross profit3 months2018-04-01 to 2018-06-30$7.20bnus-gaap:GrossProfit
Gross profit6 months2018-01-01 to 2018-06-30$14.06bnus-gaap:GrossProfit
Operating income3 months2018-04-01 to 2018-06-30−$1.59bnus-gaap:OperatingIncomeLoss
Operating income6 months2018-01-01 to 2018-06-30$359.0mus-gaap:OperatingIncomeLoss
Income tax3 months2018-04-01 to 2018-06-30$497.0mus-gaap:IncomeTaxExpenseBenefit
Income tax6 months2018-01-01 to 2018-06-30$969.0mus-gaap:IncomeTaxExpenseBenefit
Net income3 months2018-04-01 to 2018-06-30−$2.56bnus-gaap:NetIncomeLoss
Net income6 months2018-01-01 to 2018-06-30−$1.56bnus-gaap:NetIncomeLoss
Diluted EPS3 months2018-04-01 to 2018-06-30−$2.52us-gaap:EarningsPerShareDiluted
Diluted EPS6 months2018-01-01 to 2018-06-30−$1.54us-gaap:EarningsPerShareDiluted
Basic EPS3 months2018-04-01 to 2018-06-30−$2.52us-gaap:EarningsPerShareBasic
Basic EPS6 months2018-01-01 to 2018-06-30−$1.54us-gaap:EarningsPerShareBasic
Diluted shares (weighted)3 months2018-04-01 to 2018-06-301,018,000,000 sharesus-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
Diluted shares (weighted)6 months2018-01-01 to 2018-06-301,017,000,000 sharesus-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
Operating cash flow6 months2018-01-01 to 2018-06-30$5.29bnus-gaap:NetCashProvidedByUsedInOperatingActivities
Capital expenditure6 months2018-01-01 to 2018-06-30$912.0mus-gaap:PaymentsToAcquirePropertyPlantAndEquipment
Dividends paid6 months2018-01-01 to 2018-06-30$1.02bnus-gaap:PaymentsOfDividends
Cash and equivalentsAt period end2018-06-30$43.81bnus-gaap:CashAndCashEquivalentsAtCarryingValue
Current assetsAt period end2018-06-30$73.79bnus-gaap:AssetsCurrent
Total assetsAt period end2018-06-30$133.29bnus-gaap:Assets
Current liabilitiesAt period end2018-06-30$31.49bnus-gaap:LiabilitiesCurrent
Total liabilitiesAt period end2018-06-30$97.68bnus-gaap:Liabilities
Long-term debtAt period end2018-06-30$61.57bnus-gaap:LongTermDebtNoncurrent
Current portion of debtAt period end2018-06-30$3.54bnus-gaap:LongTermDebtCurrent
Shareholders' equityAt period end2018-06-30$35.61bnus-gaap:StockholdersEquity

Source: SEC EDGAR, the filing index for accession 0001558370-18-006683. Last ingested by Listed: Nov 6, 2026, 17:47 ET. Listed shows no prices and gives no investment advice.